Kingchem (Liaoning) Life Science Co., Ltd. (SHE:301509)
China · Delayed Price · Currency is CNY 38.76
-0.82 (-2.07%)
Feb 11, 2026, 4:00 PM EST
SHE:301509 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 597.3 | 496.79 | 766.71 | 716.22 | 547.15 | 462.68 |
Other Revenue | 0.23 | 0.23 | 0.12 | 0.45 | 2.05 | 1.74 |
| 597.53 | 497.01 | 766.82 | 716.67 | 549.19 | 464.42 | |
Revenue Growth (YoY) | 5.21% | -35.19% | 7.00% | 30.50% | 18.25% | 11.83% |
Cost of Revenue | 362.6 | 341.97 | 421.48 | 413.02 | 337.99 | 283.17 |
Gross Profit | 234.93 | 155.04 | 345.35 | 303.65 | 211.2 | 181.25 |
Selling, General & Admin | 111.35 | 107.68 | 115.12 | 107.52 | 88.58 | 77.05 |
Research & Development | 32.02 | 35.53 | 30.04 | 25.99 | 24.63 | 21.17 |
Other Operating Expenses | 10.55 | 6.17 | 6.12 | 5.37 | 4.06 | 3.17 |
Operating Expenses | 154.61 | 147.44 | 154.35 | 136.26 | 118.75 | 101.78 |
Operating Income | 80.32 | 7.59 | 191 | 167.39 | 92.45 | 79.47 |
Interest Expense | -0.26 | -0.32 | -2.2 | -2.71 | -2.48 | -3.22 |
Interest & Investment Income | 31.5 | 25.19 | 8.64 | 0.74 | 0.55 | 0.31 |
Currency Exchange Gain (Loss) | 4.1 | 4.1 | 1.8 | 21.56 | -2.74 | -7.34 |
Other Non Operating Income (Expenses) | -2.87 | 0.55 | 2.15 | -2.39 | 0.38 | -3.2 |
EBT Excluding Unusual Items | 112.79 | 37.11 | 201.38 | 184.6 | 88.15 | 66.02 |
Gain (Loss) on Sale of Investments | 3.87 | 0.46 | - | -0.36 | -0.04 | -0.04 |
Gain (Loss) on Sale of Assets | -0.59 | -0.59 | -0.49 | - | 0.03 | 0.01 |
Asset Writedown | -13 | -4.07 | -0.36 | -0.05 | -0.66 | -1.82 |
Other Unusual Items | 9.87 | 6.24 | 2.88 | 9.59 | 12.36 | 4.53 |
Pretax Income | 113.06 | 39.26 | 203.41 | 193.77 | 99.84 | 68.71 |
Income Tax Expense | 10.32 | 0.66 | 29.83 | 32.32 | 15.29 | 9.77 |
Net Income | 102.75 | 38.61 | 173.57 | 161.45 | 84.55 | 58.94 |
Net Income to Common | 102.75 | 38.61 | 173.57 | 161.45 | 84.55 | 58.94 |
Net Income Growth | 54.14% | -77.76% | 7.51% | 90.96% | 43.46% | 1.33% |
Shares Outstanding (Basic) | 122 | 121 | 100 | 90 | 90 | 70 |
Shares Outstanding (Diluted) | 122 | 121 | 100 | 90 | 90 | 70 |
Shares Change (YoY) | 1.86% | 20.26% | 10.97% | 0.77% | 28.18% | - |
EPS (Basic) | 0.85 | 0.32 | 1.73 | 1.79 | 0.94 | 0.84 |
EPS (Diluted) | 0.85 | 0.32 | 1.73 | 1.79 | 0.94 | 0.84 |
EPS Growth | 51.32% | -81.50% | -3.12% | 89.50% | 11.92% | 1.61% |
Free Cash Flow | 143.62 | 100.8 | 82.26 | 114.86 | -98.39 | 19.13 |
Free Cash Flow Per Share | 1.18 | 0.83 | 0.82 | 1.27 | -1.10 | 0.27 |
Dividend Per Share | 0.400 | 0.400 | 0.571 | - | - | - |
Dividend Growth | -30.00% | -30.00% | - | - | - | - |
Gross Margin | 39.32% | 31.19% | 45.04% | 42.37% | 38.46% | 39.03% |
Operating Margin | 13.44% | 1.53% | 24.91% | 23.36% | 16.83% | 17.11% |
Profit Margin | 17.20% | 7.77% | 22.63% | 22.53% | 15.39% | 12.69% |
Free Cash Flow Margin | 24.04% | 20.28% | 10.73% | 16.03% | -17.91% | 4.12% |
EBITDA | 144.53 | 72.5 | 256.84 | 219.14 | 135.15 | 115.06 |
EBITDA Margin | 24.19% | 14.59% | 33.49% | 30.58% | 24.61% | 24.77% |
D&A For EBITDA | 64.21 | 64.91 | 65.85 | 51.75 | 42.7 | 35.59 |
EBIT | 80.32 | 7.59 | 191 | 167.39 | 92.45 | 79.47 |
EBIT Margin | 13.44% | 1.53% | 24.91% | 23.36% | 16.83% | 17.11% |
Effective Tax Rate | 9.13% | 1.67% | 14.67% | 16.68% | 15.32% | 14.22% |
Revenue as Reported | 597.53 | 497.01 | 766.82 | 716.67 | - | - |
Advertising Expenses | - | 2.37 | 2.38 | 1.81 | 0.81 | 0.99 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.